Gregory F Guzauskas (Greg Guzauskas)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 14

Top Venues

Annals of internal medicine

Journal of medical economics

Neurology. Clinical practice

Leukemia & lymphoma

University of Washington

University of Washington (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Washington Nov 01 2013

United States

Senior Research Scientist :: Pharmacy

Education History

University of Washington

United States

PHD

Publications

Gregory F Guzauskas, Sarah J Tabrizi, Jeffrey D Long, Astri Arnesen, Jamie L Hamilton, Daniel O Claassen, Lorraine R Munetsi, Shahid Malik, Aubri M Kottek, Talaha M Ali, Frank Zhang
Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments: A Decision-Modeling Analysis. Neurology. Clinical practice 14 (5) (2024)
Gregory F Guzauskas, Sarah J Tabrizi, Jeffrey D Long, Astri Arnesen, Jamie L Hamilton, Daniel O Claassen, Lorraine R Munetsi, Shahid Malik, Aubri M Kottek, Talaha M Ali, Frank Zhang
Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments: A Decision-Modeling Analysis. Neurology. Clinical practice 14 (5) (2024)
Gregory F Guzauskas, Shawn Garbett, Zilu Zhou, Jonathan S Schildcrout, John A Graves, Marc S Williams, Jing Hao, Laney K Jones, Scott J Spencer, Shangqing Jiang, David L Veenstra, Josh F Peterson
Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis. Annals of internal medicine (2023)
Gregory F Guzauskas, Shawn Garbett, Zilu Zhou, Jonathan S Schildcrout, John A Graves, Marc S Williams, Jing Hao, Laney K Jones, Scott J Spencer, Shangqing Jiang, David L Veenstra, Josh F Peterson
Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis. Annals of internal medicine 176 (5) (2023)
Robert M Centor, Gregory F Guzauskas, Josh F Peterson
Annals On Call - When Might Genomic Screening Be Cost-Effective? Annals of internal medicine (2023)
Gregory F Guzauskas, Shawn Garbett, Zilu Zhou, Jonathan S Schildcrout, John A Graves, Marc S Williams, Jing Hao, Laney K Jones, Scott J Spencer, Shangqing Jiang, David L Veenstra, Josh F Peterson
Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis. Annals of internal medicine (2023)
Josh F Peterson, David L Veenstra, Marc S Williams, Jing Hao, Gregory F Guzauskas
Population Genomic Screening for Three Common Hereditary Conditions. Annals of internal medicine 176 (11) (2023)
Gregory F Guzauskas, Timothy B Hallett
The long-term impact and value of curative therapy for HIV: a modelling analysis. Journal of the International AIDS Society 26 (9) (2023)
Gregory F Guzauskas, Shawn Garbett, Zilu Zhou, Jonathan S Schildcrout, John A Graves, Marc S Williams, Jing Hao, Laney K Jones, Scott J Spencer, Shangqing Jiang, David L Veenstra, Josh F Peterson
Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis. Annals of internal medicine 176 (5) (2023)
Nanxin Li, Eileen K Sawyer, Konrad Maruszczyk, Gregory F Guzauskas, Marta T Slomka, Tom Burke, Antony Paul Martin, Jamie O'Hara, Matthew D Stevenson, Michael Recht
Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. Journal of medical economics 24 (1) (2021)
Josh J Carlson, Gregory F Guzauskas, Robert A Dann, Scott D Ramsey
Budget impact analysis of the DiviTum TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer. Journal of medical economics 24 (1) (2021)
David L Veenstra, Gregory F Guzauskas, Josh Peterson, Dina A Hassen, Susan Snyder, Jing Hao, Marc S Williams
Cost-effectiveness of population genomic screening. Genetics in medicine : official journal of the American College of Medical Genetics 21 (12) (2019)
Gregory F Guzauskas, Anthony Masaquel, Per-Olof Thuresson, Keith Dawson, David L Veenstra
Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States. Leukemia & lymphoma 60 (7) (2019)
Gregory F Guzauskas, Anthony Masaquel, Carolina Reyes, Coen Bernaards, Tania Krivasi, David L Veenstra
Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US. Journal of medical economics 21 (10) (2018)

Gregory F Guzauskas.css-eqlu8i{font-size:small;padding-left:4px;} (Greg Guzauskas)

Publication Activity (10 Years)

Top Topics

Top Venues

Gregory F Guzauskas (Greg Guzauskas)